Methotrexate (MTX) is used as an anchor disease-modifying anti-rheumatic drugs
(DMARDs) in treating rheumatoid arthritis (RA) because of its potent efficacy and tolerability …

Transporters in proximal renal tubules contribute to the disposition of numerous drugs.
Furthermore, the molecular mechanisms of tubular secretion have been progressively …

Developed over 70 years ago as an anti-folate chemotherapy agent, methotrexate (MTX) is
a WHO 'essential medicine'that is now widely employed as a first-line treatment in auto …

Antirheumatic agents are among commonly used drugs associated with adverse hepatic
reactions. Sulfasalazine and azathioprine are among the most important causes of acute …

Objective To investigate the uptake of a poly (amidoamine) dendrimer (generation 5 [G5])
nanoparticle covalently conjugated to polyvalent folic acid (FA) as the targeting ligand into …

Abstract Objective Low dose (10–25 mg/week) methotrexate is widely used for the
management of systemic inflammatory diseases, and is considered to be relatively safe …

Methotrexate (MTX) is the anchor disease-modifying antirheumatic drug (DMARD) in
rheumatoid arthritis (RA) treatment. It is used in monotherapy and/or in combination with …

In this review, we especially cover the following themes: new clinical studies on the use of
MTX in RA, the use of MTX in other rheumatic conditions, prediction of response to MTX …

We investigated the effect of single-nucleotide polymorphisms (SNPs) spanning 10
methotrexate (MTX) pathway genes, namely AMPD1, ATIC, DHFR, FPGS, GGH, ITPA …

Methotrexate (MTX) is the central drug in the management of rheumatoid arthritis (RA) and
other immune mediated inflammatory diseases. It is widely used either in monotherapy or in …